Clinical significance of metastatic-tumor HER2 status in patients with HER2-positive primary breast cancer

被引：0
|
作者：
Niikura, N.
Liu, J.
Hayashi, N.
Mittendorf, E. A.
Gong, Y.
Palla, S. L.
Tokuda, Y.
Gonzalez-Angulo, A. M.
Hortobagyi, G. N.
Ueno, N. T.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Tokai Univ, Sch Med, Kanagawa 2591100, Japan
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
545
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HER2 mutation status in Japanese HER2-positive breast cancer patients
    Endo, Yumi
    Dong, Yu
    Kondo, Naoto
    Yoshimoto, Nobuyasu
    Asano, Tomoko
    Hato, Yukari
    Nishimoto, Mayumi
    Kato, Hiroyuki
    Takahashi, Satoru
    Nakanishi, Ryoichi
    Toyama, Tatsuya
    BREAST CANCER, 2016, 23 (06) : 902 - 907
  • [2] HER2 mutation status in Japanese HER2-positive breast cancer patients
    Yumi Endo
    Yu Dong
    Naoto Kondo
    Nobuyasu Yoshimoto
    Tomoko Asano
    Yukari Hato
    Mayumi Nishimoto
    Hiroyuki Kato
    Satoru Takahashi
    Ryoichi Nakanishi
    Tatsuya Toyama
    Breast Cancer, 2016, 23 : 902 - 907
  • [3] HER2 status of circulating tumor cells in HER2-positive metastatic breast cancer patients: A valuable biomarker in anti-HER2 therapy
    Jiang, Z.
    Li, L.
    Liu, Y.
    Wang, T.
    Zhang, S.
    Yuan, Y.
    Bian, L.
    Liu, Q.
    Qi, F.
    CANCER RESEARCH, 2013, 73
  • [4] Targeting HER2 in patients with HER2-negative metastatic breast cancer with elevated serum levels of the HER2 extracellular domain and/or HER2-positive circulating tumor cells in the clinical routine
    Kurbacher, C. M.
    Quade, A.
    Kunstmann, G.
    Herz, S.
    Kurbacher, J. A.
    Warm, M. A.
    ANNALS OF ONCOLOGY, 2015, 26
  • [5] Radiolabeled trastuzumab biodistribution and serum HER2 levels in HER2-positive metastatic breast cancer patients
    Perik, Patrick J.
    Lub-de Hogge, Marjolijn N.
    Gietema, Jourik A.
    Jager, Piet L.
    Kosterink, Jos G.
    de Korte, Sander A.
    van Veldhuisen, Drik J.
    van der Graaf, Winette T.
    Sieijfer, Drik T.
    de Vries, Elisabeth G.
    ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
  • [6] Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, T.
    Solomayer, E.
    Uhr, J.
    Wallwiener, D.
    ONKOLOGIE, 2008, 31 : 51 - 51
  • [7] HER2Δ16 expression in HER2-positive breast cancer
    De Yao, Jocelyn Torres
    Sun, Danyu
    Galehouse, Donna
    Shorten, Scott
    Haller, Nairmeen
    Rehmus, Esther Hoogland
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
    Lee, Hee Jin
    Seo, An Na
    Kim, Eun Joo
    Jang, Min Hye
    Suh, Koung Jin
    Ryu, Han Suk
    Kim, Yu Jung
    Kim, Jee Hyun
    Im, Seock-Ah
    Gong, Gyungyub
    Jung, Kyung Hae
    Park, In Ae
    Park, So Yeon
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (06) : 755 - 766
  • [9] HER2Δ16 expression in HER2-positive breast cancer
    De Yao, Jocelyn Torres
    Sun, Danyu
    Galehouse, Donna
    Shorten, Scott
    Haller, Nairmeen Awad
    Rehmus, Esther Hoogland
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [10] Reassessment of HER2 status in breast cancer patients at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, Tania
    TUMOR BIOLOGY, 2007, 28 : 22 - 22
12345